Drugs & Aging

, Volume 20, Issue 1, pp 23–57

Demographics, Assessment and Management of Pain in the Elderly

Therapy in Practice

Abstract

The prevalence of pain increases with each decade of life. Pain in the elderly is distinctly different from pain experienced by younger individuals. Cancer is a leading cause of pain; however, other conditions that cause pain such as facet joint arthritis (causing low back pain), polymyalgia rheumatica, Paget’s disease, neuropathies, peripheral vascular disease and coronary disease most commonly occur in patients over the age of 50 years. Poorly controlled pain in the elderly leads to cognitive failure, depression and mood disturbance and reduces activities of daily living. Barriers to pain management include a sense of fatalism, denial, the desire to be ‘the good patient’, geographical barriers and financial limitations.

Aging causes physiological changes that alter the pharmacokinetics and pharmacodynamics of analgesics, narrowing their therapeutic index and increasing the risk of toxicity and drug-drug interactions. CNS changes lead to an increased risk of delirium.

Assessment among the verbal but cognitively impaired elderly is satisfactorily accomplished with the help of unidimensional and multidimensional pain scales. A comprehensive physical examination and pain history is essential, as well as a review of cognitive function and activities of daily living. The goal of pain management among the elderly is improvement in pain and optimisation of activities of daily living, not complete eradication of pain nor the lowest possible drug dosages. Most successful management strategies combine pharmacological and nonpharmacological (home remedies, massage, topical agents, heat and cold packs and informal cognitive strategies) therapies.

A basic principle of the pharmacological approach in the elderly is to start analgesics at low dosages and titrate slowly. The WHO’s three-step guideline to pain management should guide prescribing. Opioid choices necessitate an understanding of pharmacology to ensure safe administration in end-organ failure and avoidance of drug interactions. Adjuvant analgesics are used to reduce opioid adverse effects or improve poorly controlled pain. Adjuvant analgesics (NSAIDs, tricyclic antidepressants and antiepileptic drugs) are initiated prior to opioids for nociceptive and neuropathic pain. Preferred adjuvants for nociceptive pain are short-acting paracetamol (acetaminophen), NSAIDs, cyclo-oxygenase-2 inhibitors and corticosteroids (short-term). Preferred drugs for neuropathic pain include desipramine, nortriptyline, gabapentin and valproic acid. Drugs to avoid are pentazocine, pethidine (meperidine), dextropropoxyphene and opioids that are both an agonist and antagonist, ketorolac, indomethacin, piroxicam, mefenamic acid, amitriptyline and doxepin. The type of pain, and renal and hepatic function, alter the preferred adjuvant and opioid choices. Selection of the appropriate analgesics is also influenced by versatility, polypharmacy, severity and type of pain, drug availability, associated symptoms and cost.

References

  1. 1.
    Cleary JR, Carbone PP. Palliative medicine in the elderly. Cancer 1997 Oct; 80(7): 1335–47PubMedGoogle Scholar
  2. 2.
    Overcash J. Symptom management in the geriatric patient. Cancer Control 1998 May; 5(3): 46–7PubMedGoogle Scholar
  3. 3.
    Gloth FM. Pain management in older adults: prevention and treatment. J Am Geriatr Soc 2001 Feb; 49(2): 188–99PubMedGoogle Scholar
  4. 4.
    Medling PS. Is there such a thing as geriatric pain? Pain 1991 Aug; 46(2): 119–21Google Scholar
  5. 5.
    Weiner DK, Hanlon JT. Pain in nursing home residents: management strategies. Drugs Aging 2001; 18(1): 13–29PubMedGoogle Scholar
  6. 6.
    Ferrell BA. Pain evaluation and management in the nursing home. Ann Intern Med 1995 Nov; 123(9): 681–7PubMedGoogle Scholar
  7. 7.
    Ferrell BA, Ferrell BR, Rivera L. Pain in cognitively impaired nursing home patients. J Pain Symptom Manage 1995 Nov; 10(8): 591–8PubMedGoogle Scholar
  8. 8.
    Severn AM, Dodds C. Cognitive dysfunction may complicate assessment of pain in elderly patients [letter]. BMJ 1997 Aug; 315(7107): 551PubMedGoogle Scholar
  9. 9.
    Ferrell BA, Stein WM, Beck JC. The Geriatric Pain Measure: validity, reliability and factor analysis. J Am Geriatr Soc 2000 Dec; 48(12): 1669–73PubMedGoogle Scholar
  10. 10.
    American Geriatrics Society. The management of chronic pain in older persons: AGS panel on chronic pain in older persons. J Am Geriatr Soc 1998 May; 46(5): 635–51Google Scholar
  11. 11.
    Lansbury G. Chronic pain management: a qualitative study of elderly people’s preferred coping strategies and barriers to management. Disabil Rehabil 2000 Jan; 22(1–2): 2–14PubMedGoogle Scholar
  12. 12.
    Ward SE, Goldberg N, Miller-McCauley V, et al. Patient-related barriers to management of cancer pain. Pain 1993 Mar; 52(3): 319–24PubMedGoogle Scholar
  13. 13.
    Cleeland CS. Undertreatment of cancer pain in elderly patients. JAMA 1998 Jun; 279(23): 1914–5PubMedGoogle Scholar
  14. 14.
    Von Roenn JH. Are we the barrier? J Clin Oncol 2001 Dec; 19(23): 4273–4Google Scholar
  15. 15.
    Bernabei R, Gambassi G, Lapane K, et al. Management of pain in elderly patients with cancer. SAGE Study Group Systematic Assessment of Geriatric Drug Use via Epidemiology. JAMA 1998 Jun; 279(23): 1877–82PubMedGoogle Scholar
  16. 16.
    Nikolaus T. Assessment of chronic pain in elderly patients. Ther Umsch 1997 Jun; 54(6): 340–4PubMedGoogle Scholar
  17. 17.
    Kewman DG, Vaishampayan N, Zald D, et al. Cognitive impairment in musculoskeletal pain patients. Int J Psychiatry Med 1991; 21(3): 253–62PubMedGoogle Scholar
  18. 18.
    Lamberg L. Chronic pain linked with poor sleep; exploration of causes of treatment. JAMA 1999 Feb; 281(8): 691–2PubMedGoogle Scholar
  19. 19.
    Schnurr RF, MacDonald MR. Memory complaints of chronic pain. Clin J Pain 1995; 11(2): 103–11PubMedGoogle Scholar
  20. 20.
    Eccleston C. Chronic pain and attention: a cognitive approach. Br J Clin Psychol 1994; 33(4): 535–47PubMedGoogle Scholar
  21. 21.
    Guay DR. Adjunctive agents in the management of chronic pain. Pharmacotherapy 2001 Sep; 21(9): 1070–81PubMedGoogle Scholar
  22. 22.
    Tumer N, Scarpace PJ, Lowenthal DT. Geriatric pharmacology: basic and clinical considerations. Annu Rev Pharmacol Toxicol 1992; 32: 271–302PubMedGoogle Scholar
  23. 23.
    Flacker JM, Lipsitz LA. Neural mechanisms of delirium: current hypotheses and evolving concepts. J Gerontol A Biol Sci Med Sci 1999 Jun; 54(6): B239–46PubMedGoogle Scholar
  24. 24.
    Coyle N, Breitbart W, Weaver S, et al. Delirium as a contributing factor to “crescendo” pain: three case reports. J Pain Symptom Manage 1994 Jan; 9(1): 44–7PubMedGoogle Scholar
  25. 25.
    Gibson MC, Schroder C. The many faces of pain for older, dying adults. Am J Hosp Palliat Care 2001 Jan–Feb; 18(1): 19–25PubMedGoogle Scholar
  26. 26.
    Bergh I, Sjostrom B, Oden A, et al. An application of pain rating scales in geriatric patients. Aging 2000 Oct; 12(5): 380–7PubMedGoogle Scholar
  27. 27.
    Freedman G, Peruvemba R. Geriatric pain management. The anesthesiologist’s perspective. Anesthesiol Clin North Am 2000; 18(1): 123–41Google Scholar
  28. 28.
    Rosenberg SK, Boswell MV. Pain management in geriatric. In: Weiner RS, editor. Pain management: a practical guide for clinicians. Boca Raton (FL): St Lucie Press, 1998: 683–92Google Scholar
  29. 29.
    Farrell MJ, Katz B, Helme RD. The impact of dementia on the pain experience. Pain 1996; 67: 7–15PubMedGoogle Scholar
  30. 30.
    Angst MS, Brose W, Dyck JB. The relationship between the visual analog pain intensity and pain relief scale changes during analgesic drug studies in chronic pain patients. Anesthesiology 1999; 91(1): 34–41PubMedGoogle Scholar
  31. 31.
    Porter FL, Malhotra KM, Wolf CM, et al. Dementia and response to pain in the elderly. Pain 1996; 68: 413–21PubMedGoogle Scholar
  32. 32.
    Barkwell DP. Ascribed meaning: a critical factor in coping and pain attenuation in patients with cancer-related pain. J Palliat Care 1991; 7(3): 5–14PubMedGoogle Scholar
  33. 33.
    Kappauf HW. Oncologic pain therapy: are there alternatives to pill and high-tech? MMW Fortschr Med 1999; 142(42): 38–41Google Scholar
  34. 34.
    Pincus T, Williams A. Models of psychosomatic research. J Psychosom Res 1999; 47(3): 211–9PubMedGoogle Scholar
  35. 35.
    Fishbain DA, Cutler R, Rosomoff HL, et al. Chronic pain-associated depression: antecedent or consequence of chronic pain? A review. Clin J Pain 1997; 13(2): 116–37PubMedGoogle Scholar
  36. 36.
    Proctor T, Gatchel RJ, Robinson RC. Psychosocial factors and risk of pain and disability. Occup Med 2000; 15(4): 803–12PubMedGoogle Scholar
  37. 37.
    Zaza C, Stolee P, Prkachin K. The application of goal attainment scaling in chronic pain settings. J Pain Symptom Manage 1999; 17(1): 55–64PubMedGoogle Scholar
  38. 38.
    Gatchel RJ. A biopsychosocial overview of pretreatment screening of patients with pain. Clin J Pain 2001; 17(3): 192–9PubMedGoogle Scholar
  39. 39.
    Eccelston C. Role of psychology in pain management. Br J Anaesth 2001; 87(1): 144–52Google Scholar
  40. 40.
    Cutler RB, Fishbain DA, Lu Y, et al. Prediction of pain center treatment outcome for geriatric chronic pain patients. Clin J Pain 1994; 10(1): 1–2Google Scholar
  41. 41.
    Anonymous. Integration of behavioral and relaxation approaches into the treatment of chronic benign pain and insomnia: NIH technology assessment panel on integration and behavioral and relaxation approaches into the treatment of chronic pain and insomnia. JAMA 1996; 276(4): 313–8Google Scholar
  42. 42.
    Morley S, Eccelston C, Williams A. Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache [online]: Database of Abstracts of Reviews of Effectiveness 2002. Available from URL: http://nhscrd.york.ac.uk/online/dare/990758.htm [Accessed 2002 Nov 11]Google Scholar
  43. 43.
    Flor H, Birbaumer M, Schugens MM, et al. Symptom-specific psychophysiological responses in chronic pain patients. Psychophysiology 1992; 29(4): 452–60PubMedGoogle Scholar
  44. 44.
    Flor H, Fydrich T, Turk DC. Efficacy of multidisciplinary pain treatment centers: a meta-analytic review. Pain 1992; 49(2): 221–30PubMedGoogle Scholar
  45. 45.
    Morley S, Eccelston C, Williams A. Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain 1999; 80: 1–13PubMedGoogle Scholar
  46. 46.
    Ciccone DS, Grezesiak RC. Cognitive dimensions of chronic pain. Soc Sci Med 1984; 19(12): 1339–45PubMedGoogle Scholar
  47. 47.
    Roche RJ, Forman WB. Pain management for the geriatric patient. Clin Podiatr Med Surg 1994; 11(1): 41–53PubMedGoogle Scholar
  48. 48.
    Turk DC. Remember the distinction between malignant and benign pain?: well, forget it. Clin J Pain 2002; 18: 75–6PubMedGoogle Scholar
  49. 49.
    Sorge J. The lesson from cancer pain. Eur J Pain 2000; 4Suppl. A: 3–7PubMedGoogle Scholar
  50. 50.
    Egberts ACG, Lenderink AW, de Koning FHP. Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment. J Clin Pharmacol 1997; 17(3): 149–55Google Scholar
  51. 51.
    Bellville JW, Forrest WH, Miller E. Influence of age on pain relief from analgesics: a study of postoperative patients. JAMA 1971 Sep; 217(13): 1835–41PubMedGoogle Scholar
  52. 52.
    Kaiko RF. Age and morphine analgesia in cancer patients with postoperative pain. Clin Pharmacol Ther 1980; 28(6): 823–6PubMedGoogle Scholar
  53. 53.
    McLeod PJ, Huang AR, Tamblyn RM, et al. Defining inappropriate practices in prescribing for elderly people: a national consensus panel. Can Med Assoc J 1997 Feb; 156(3): 385–91Google Scholar
  54. 54.
    Ferry JJ, Wagner JG. The non-linear pharmacokinetics of prednisone and prednisolone. Biopharm Drug Dispos 1986 Jan–Feb;7(1): 91–101PubMedGoogle Scholar
  55. 55.
    Greenberger PA, Chow MJ, Atkinson AJ, et al. Comparison of prednisolone kinetics in patients receiving daily or alternate-day prednisone for asthma. Clin Pharmacol Ther 1986 Feb; 32(9): 163–8Google Scholar
  56. 56.
    Magee MH, Blum RA, Lates CD, et al. Clinical pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol 2001 Nov; 41(11): 1180–94PubMedGoogle Scholar
  57. 57.
    Faure C, Andre J, Pelatan C, et al. Pharmacokinetics of intravenous methylprednisolone and oral prednisone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. Eur J Clin Pharmacol 1998; 54(7): 555–60PubMedGoogle Scholar
  58. 58.
    Garg V, Jusko WJ. Bioavailability and reversible metabolism of prednisone and prednisolone in man. Biopharm Drug Dispos 1994 Mar; 15(2): 162–72Google Scholar
  59. 59.
    Cavanaugh JH, Karol MD. Lack of pharmacokinetic interaction after administration of lansoprazole or omeprazole with prednisone. J Clin Pharmacol 1996 Nov; 36(11): 1064–71PubMedGoogle Scholar
  60. 60.
    Leburn-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001 May; 51(5): 443–50Google Scholar
  61. 61.
    Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet 1990 Aug; 19(2): 126–46PubMedGoogle Scholar
  62. 62.
    Toth GG, Kloosterman C, Uges DR, et al. Pharmacokinetics of high-dose oral and intravenous dexamethasone. Ther Drug Monit 1999 Oct; 21(5): 532–5PubMedGoogle Scholar
  63. 63.
    O’Sullivan BT, Cutler DJ, Hunt GE, et al. Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects. Biol Psychiatry 1997 Mar; 41(5): 574–84PubMedGoogle Scholar
  64. 64.
    Elliott CL, Read GF, Wallace EM, et al. The pharmacokinetics of oral and intramuscular administration of dexamethasone in late pregnancy. Acta Obstet Gynecol Scand 1996 Mar; 75(3): 213–6PubMedGoogle Scholar
  65. 65.
    Lamiable D, Vistelle R, Sulmont V, et al. Pharmacokinetics of dexamethasone administered orally in obese patients. Therapie 1990 Jul–Aug; 45(4): 311–4PubMedGoogle Scholar
  66. 66.
    Guthrie SK, Heidt M, Pande A, et al. A longitudinal evaluation of dexamethasone pharmacokinetics in depressed patients and normal controls. J Clin Psychopharmacol 1992 Jun; 12(3): 191–6PubMedGoogle Scholar
  67. 67.
    Miller LG. Cigarettes and drug therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharm 1990 Feb; 9(2): 125–35PubMedGoogle Scholar
  68. 68.
    Cummings DM, Larijani GE, Conner DP, et al. Characterization of dexamethasone binding in normal and uremic human serum. DICP 1990 Mar; 24(3): 29–31Google Scholar
  69. 69.
    Brady ME, Sartiano GP, Rosenblum SL, et al. The pharmacokinetics of single high doses of dexamethasone in cancer patients. Eur J Clin Pharmacol 1987; 32(6): 593–6PubMedGoogle Scholar
  70. 70.
    Kutemeyer S, Schurmeyer TH, von zur Muhlen A. Effect of liver damage on the pharmacokinetics of dexamethasone. Eur J Endocrinol 1994 Dec; 131(6): 594–7PubMedGoogle Scholar
  71. 71.
    Gupta SK, Ritchie JC, Ellinwood EH, et al. Modeling the pharmacokinetics and pharmacodynamics of dexamethasone in depressed patients. Eur J Clin Pharmacol 1992; 43(1): 51–5PubMedGoogle Scholar
  72. 72.
    Maguire KP, Tuckwell VM, Schweitzer I, et al. Dexamethasone kinetics in depressed patients before and after clinical response. Psychoneuroendocrinology 1990; 15(2): 113–23PubMedGoogle Scholar
  73. 73.
    Lewis KP, Stanley GD. Pharmacology. In: Gilbertson LI, editor. Conscious sedation. Philadelphia (PA): Lippincott Williams & Wilkins, 1999: 73–86Google Scholar
  74. 74.
    Davis MP, Homsi J. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer 2001; 9: 442–51PubMedGoogle Scholar
  75. 75.
    American Society of Anesthesiologists Task Force on Pain Management, Cancer Pain Section. Practice guidelines for cancer pain management: a report. Anesthesiology 1996; 84(5): 1243–57Google Scholar
  76. 76.
    Donnelly S, Davis MP, Walsh D, et al. Morphine in cancer pain management: a practical guide. Support Care Cancer 2002; 10: 13–35PubMedGoogle Scholar
  77. 77.
    Hanks GW, de Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001; 84(5): 587–93PubMedGoogle Scholar
  78. 78.
    Duggleby W, Lander J. Cognitive status and postoperative pain: older adults. J Pain Symptom Manage 1994; 9(1): 19–27PubMedGoogle Scholar
  79. 79.
    De Stoutz ND, Bruera E, Surarez-Alamzor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995 Jul; 10(5): 378–84PubMedGoogle Scholar
  80. 80.
    Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol 2002; 20(1): 348–52PubMedGoogle Scholar
  81. 81.
    Tawfik MO, Elborolossy K, Nasr F. Tramadol hydrochloride in relief of cancer pain: a double blind comparison against sustained release morphine [abstrac]. Pain 1990; Suppl. 5: S377Google Scholar
  82. 82.
    Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioid in liver disease. Clin Pharmacokinet 1999 Jul; 37(1): 17–40PubMedGoogle Scholar
  83. 83.
    Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 1: clinical considerations. J Pain Symptom Manage 2001; 21(2): 144–50PubMedGoogle Scholar
  84. 84.
    Dionne RA, Lepinski AM, Gordon SM, et al. Analgesic effects of peripherally administered opioids in clinical models of acute and chronic inflammation. Clin Pharmacol Ther 2001 Jul; 70(1): 66–73PubMedGoogle Scholar
  85. 85.
    Twillman RK, Long TD, Cathers TA, et al. Treatment of painful skin ulcers with topical opioids. J Pain Symptom Manage 1999 Apr; 17(4): 288–92PubMedGoogle Scholar
  86. 86.
    Krajnik M, Zylicz Z, Finlay I. Potential uses of topical opioids in palliative care: report of 6 cases. Pain 1999 Mar; 80(1–2): 121–5PubMedGoogle Scholar
  87. 87.
    Boulton DW, Arnaud P, DeVane CL. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin Pharmacol Ther 2001 Jul; 70(1): 48–57PubMedGoogle Scholar
  88. 88.
    Davis MP, Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 2001; 9: 73–83PubMedGoogle Scholar
  89. 89.
    Peng PW, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology1999 Feb; 90(2): 576–99PubMedGoogle Scholar
  90. 90.
    Breitbart W, Chandler S, Eagel B, et al. An alternative algorithm for dosing transdermal fentanyl for cancer-related pain. Oncology 2000 May; 14(5): 695–705PubMedGoogle Scholar
  91. 91.
    Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC (r)) and morphine sulfate immediate release (MSIR (r)). Pain 2001; 91: 123–30PubMedGoogle Scholar
  92. 92.
    Gardner-Nix J. Oral transmucosal fentanyl and sufentanil for incident pain. J Pain Symptom Manage 2001 Aug; 22(2): 627–30PubMedGoogle Scholar
  93. 93.
    Hanks GW, Fallon MT. Transdermal fentanyl in cancer pain: conversion from oral morphine [letter]. J Pain Symptom Manage 1995 Feb; 10(2): 87PubMedGoogle Scholar
  94. 94.
    Labroo RB, Paine MF, Thummel KE, et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 1997; 25(9): 1072–80PubMedGoogle Scholar
  95. 95.
    Mercadante S. Recent progress in the pharmacotherapy of cancer pain. Expert Review Anticancer Ther 2001; 1(3): 487–94Google Scholar
  96. 96.
    Poyhia R, Olkkola KT, Seppala T. The pharmacokinetics of oxycodone after intravenous injection in adults. Br J Pharmacol 1991; 32(4): 516–8Google Scholar
  97. 97.
    Poyhia R, Seppala T. solubility and protein binding of oxycodone in vitro. Pharmacol Toxicol 1994; 74: 23–7PubMedGoogle Scholar
  98. 98.
    Curtis GB, Johnson GH, Clark P, et al. Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. Eur J Clin Pharmacol 1999; 55(6): 425–9PubMedGoogle Scholar
  99. 99.
    Heiskanen T, Olkkola KT, Kalso E, et al. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998 Dec; 64(6): 603–11PubMedGoogle Scholar
  100. 100.
    Kaplan R, Parris WC, Citron ML, et al. Comparison of controlled-release and immediate release oxycodone tablets in patients with cancer pain. J Clin Oncol 1998 Oct; 16(10): 3230–7PubMedGoogle Scholar
  101. 101.
    Poyhia R, Vainio A, Kalso E. A review of oxycodone’s clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 1993 Feb; 8(2): 63–7PubMedGoogle Scholar
  102. 102.
    Bruera E, Belzile M, Pituskin E, et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 1998 Oct; 16(10): 3222–9PubMedGoogle Scholar
  103. 103.
    Gagnon B, Bielech M, Watanabe S, et al. The use of intermittent subcutaneous injections of oxycodone for opioid rotation in patients with cancer pain. Support Care Cancer 1999; 7(4): 265–70PubMedGoogle Scholar
  104. 104.
    Zhukovsky DS, Walsh D, Doona M. The relative potency between high dose oral oxycodone and intravenous morphine: a case illustration. J Pain Symptom Manage1999 Jul; 18(1): 53–5PubMedGoogle Scholar
  105. 105.
    Nielsen CK, Ross FB, Smith MT. Incomplete, asymmetric, and route-dependent cross-tolerance between oxycodone and morphine in the Dark Agouti rat. J Pharmacol Exp Ther 2000 Oct; 295(1): 91–9PubMedGoogle Scholar
  106. 106.
    Kaiko RF, Benzinger DP, Fitzmartin RD, et al. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 1996 Jan; 59(1): 52–61PubMedGoogle Scholar
  107. 107.
    Colucci RD, Swanton RE, Thomas GB, et al. Relative variability in bioavailability of oral controlled-release formulations of oxycodone and morphine. Am J Ther 2001 Jul–Aug; 8(4): 231–6PubMedGoogle Scholar
  108. 108.
    Maddocks I, Somogyi A, Abbott F, et al. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 1996 Sep; 12(3): 182–9PubMedGoogle Scholar
  109. 109.
    Takala A, Kaasalainen V, Seppala T, et al. Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. Acta Anaethesiol Scand 1997; 41: 309–12Google Scholar
  110. 110.
    Leow KP, Smith MT, Watt JA, et al. Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration. Ther Drug Monit 1992; 14: 479–84PubMedGoogle Scholar
  111. 111.
    Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 2001; 9: 84–96PubMedGoogle Scholar
  112. 112.
    Ritschel WA, Parab PV, Denson DD, et al. Absolute bioavailability of hydromorphone after peroral and rectal administration in humans: saliva/plasma ratio and clinical effects. J Clin Pharmacol 1987 Sep; 29(9): 567–53Google Scholar
  113. 113.
    Agnst MS, Drover DR, Lotsch J, et al. Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology 2001 Jan; 94(1): 63–73Google Scholar
  114. 114.
    Parab PV, Ritschel WA, Coyle DE, et al. Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration in humans. Biopharm Drug Dispos 1988 Mar–Apr; 9(2): 187–99PubMedGoogle Scholar
  115. 115.
    Coda B, Tanaka A, Jacobson RC, et al. Hydromorphone analgesia after intravenous bolus administration. Pain 1997 May; 71(1): 41–8PubMedGoogle Scholar
  116. 116.
    Wright AW, Mather LE, Smith MT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001 Jun; 69(4): 409–20PubMedGoogle Scholar
  117. 117.
    Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000 Jul; 27(7): 524–8PubMedGoogle Scholar
  118. 118.
    Lawlor P, Turner K, Hanson J, et al. Dose ratio between morphine and hydromorphone in patients with cancer pain: a retrospective study. Pain 1997 Aug; 72(1–2): 79–85PubMedGoogle Scholar
  119. 119.
    Katcher J, Walsh D. Opioid-induced itching: morphine sulfate and hydromorphone hydrochloride. J Pain Symptom Manage 1999 Jan; 17(1): 70–2PubMedGoogle Scholar
  120. 120.
    Abreu ME, Bigelow GE, Fleisher L, et al. Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacologia 2001 Feb; 154(1): 76–84Google Scholar
  121. 121.
    Miller MG, McCarthy N, O’Boyle CA. Continuous subcutaneous infusion of morphine vs hydromorphone: a controlled trial. J Pain Symptom Manage 1999 Jul; 18(1): 9–16PubMedGoogle Scholar
  122. 122.
    Bruera E, Sloan P, Mount B, et al. A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials Group. J Clin Oncol 1996 May; 14(5): 1713–7PubMedGoogle Scholar
  123. 123.
    Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996 Dec; 31(6): 410–22PubMedGoogle Scholar
  124. 124.
    Tallgren M, Olkkola KT, Seppala T, et al. Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther 1997 Jun; 61(6): 655–61PubMedGoogle Scholar
  125. 125.
    Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996 Dec; 31(6): 410–22PubMedGoogle Scholar
  126. 126.
    Lohr JW, Willsky GR, Acara MA. Renal drug metabolism. Pharmacol Rev 1998; 50(1): 107–41PubMedGoogle Scholar
  127. 127.
    Koehntop DE, Rodman JH. Fentanyl pharmacokinetics in patients undergoing renal transplantation. Pharmacotherapy 1997; 17(4): 746–52PubMedGoogle Scholar
  128. 128.
    Lee MA, Leng ME, Tiernan EJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med 2001 Jan; 15(1): 26–34PubMedGoogle Scholar
  129. 129.
    Babul N, Darke AC, Hagen N, et al. Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage 1995 Apr; 10(3): 184–6PubMedGoogle Scholar
  130. 130.
    Maurer PM, Bartkowski RR. Drug interactions of clinical significance with opioid analgesics. Drug Saf 1993; 8(1): 30–48PubMedGoogle Scholar
  131. 131.
    Galer BS, Dworkin RH. A clinical guide to neuropathic pain. New York: McGraw Hill Companies, 2000Google Scholar
  132. 132.
    Cox JM, Pappagallo M. Contemporary and emergent pharmacological therapies for chronic pain: nonopioid analgesia. Expert Rev Neurotherapeutics 2001; 1(1): 1–21Google Scholar
  133. 133.
    McQuay H, Carroll D, Jadad AR, et al. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995 Oct; 311(7012): 1047–52PubMedGoogle Scholar
  134. 134.
    Eckhardt K, Ammon S, Hofmann U, et al. Gabapentin enhances the analgesic effect of morphine in health volunteers. Anesth Analg 2000 Jul; 91(1): 185–91PubMedGoogle Scholar
  135. 135.
    Dallocchio C, Buffa C, Mazzarello P, et al. Gabapentin vs amitriptyline in painful diabetic neuropathy: an open-label pilot study. J Pain Symptom Manage 2000 Oct; 20(4): 280–5PubMedGoogle Scholar
  136. 136.
    Cutrer FM, Moskowitz MA. Wolff Award 1996. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache 1996 Nov–Dec; 36(10): 579–85PubMedGoogle Scholar
  137. 137.
    Loscher W. Valproate: a reappraisal of it pharmacodynamic properties and mechanisms of action. Prog Neurobiol 1999 May; 58(1): 31–59PubMedGoogle Scholar
  138. 138.
    Hering R, Kuritzky A. Sodium valproate in the treatment of cluster headache: an open clinical trial. Cephalalgia 1989 Sep; 9(3): 195–8PubMedGoogle Scholar
  139. 139.
    Hardy JR, Rees EJA, Gwilliam B, et al. A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain. J Pain Symptom Manage 2001 Mar; 21(3): 204–9PubMedGoogle Scholar
  140. 140.
    Tanaka E. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther 1999 Apr; 24(2): 87–92PubMedGoogle Scholar
  141. 141.
    Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998 May; 32(5): 554–63PubMedGoogle Scholar
  142. 142.
    Neumann MG, Shear MH, Jacobson-Brown PM, et al. CYP2E1-mediated modulation of valproic acid-induced hepatocytotoxicity. Clin Biochem 2001 May; 34(3): 211–8Google Scholar
  143. 143.
    Rogiers V, Akrawi M, Vercruysse A, et al. Effects of the anticonvulsant, valproate, on the expression of components of the cytochrome-P-450-mediated monooxygenase system and glutathione S-transferases. Eur J Biochem 1995; 231(2): 337–43PubMedGoogle Scholar
  144. 144.
    McQuay HJ, Carroll D, Glynn CJ. Low dose amitriptyline in the treatment of chronic pain. Anesthesia 1992 Aug; 47(8): 646–52Google Scholar
  145. 145.
    McQuay HJ, Carroll D, Glynn CJ. Dose-response for analgesic effect of amitriptyline in chronic pain. Anaesthesia 1993 Apr; 48(4): 281–5PubMedGoogle Scholar
  146. 146.
    Watson CPN. Antidepressant drugs in adjuvant analgesics. J Pain Symptom Manage 1994 Aug; 9(6): 392–405PubMedGoogle Scholar
  147. 147.
    Backonja MM. Local anesthetics as adjuvant analgesics. J Pain Symptom Manage 1994 Nov; 9(8): 491–9PubMedGoogle Scholar
  148. 148.
    Fromm GH. Baclofen as an adjuvant analgesic. J Pain Symptom Manage 1994 Nov; 9(8): 500–9PubMedGoogle Scholar
  149. 149.
    Marchettini P, Lacerenza M, Marangoni C, et al. Lidocaine test in neuralgia. Pain 1992; 48: 277–82Google Scholar

Copyright information

© Adis International Limited 2003

Authors and Affiliations

  1. 1.Harry R. Horvitz Center for Palliative MedicineCleveland Clinic FoundationClevelandUSA

Personalised recommendations